Breast Cancer
Conference Coverage
Patritumab deruxtecan shows promise for breast cancer patients
Preliminary studies show acceptable safety profiles and clinical responses that justify future trials.
Conference Coverage
T-DXd for HER2-low BC: Analysis confirms adverse effects
But T-DXd demonstrates a manageable safety profile consistent with prior reports, says the author of a new paper.
Conference Coverage
BMI has greater impact on survival in younger breast cancer patients
Study of women on endocrine therapy for breast cancer addresses the effects of BMI on survival.
From the Journals
Number of cancer survivors with functional limitations doubled in 20 years
The 70% prevalence of functional limitation among survivors in 2018 is nearly twice that of the general population.
News from the FDA/CDC
New USPSTF draft suggests mammography start at 40, not 50
“It is now clear that screening every other year starting at age 40 has the potential to save about 20% more lives among all women.”
From the Journals
Familial cancer risk complex, not limited to same site
“The findings suggest that the familial risk extends to discordant early-onset cancers, including ovarian, testicular, and pancreatic cancers, as...
From the Journals
Pausing endocrine therapy to attempt pregnancy is safe
The results provide the “strongest evidence to date on the short-term safety of this choice.”
Conference Coverage
Preop MRI does not reduce positive margins in breast surgery
“While it can provide a benefit in selected cases given its high sensitivity, MRI is associated with false positives and can also contribute to...
Conference Coverage
Mammography after breast cancer: No benefit for older patients?
“Ongoing surveillance mammography in these patients may lead to overdiagnosis and overtreatment of cancers that potentially would not harm...
From the Journals
SCC from breast implants: Negligible risk, study finds
Regarding SCC, “whether the observed elevated risk is associated with the implants is difficult to interpret because it is based on only one case...
Conference Coverage
Intraoperative pathology spurs overtreatment in mastectomy
“This study suggests that surgeons should delay ALND decision-making until a later time to avoid overtreating patients.”